Mesoblast (MESO) EBT Margin (2014 - 2023)
Mesoblast (MESO) posted quarterly EBT Margin of 1183.77% for Q2 2023, down 21673.0% year-on-year from N/an in Q2 2022, and down 23.1% on a QoQ basis from 961.63% in Q1 2023.
Mesoblast (MESO) EBT Margin (2014 - 2023) Analysis & Trends
Mesoblast (MESO) has reported EBT Margin for 10 consecutive years, with 1183.77% the latest figure, recorded in Q2 2023.
- Quarterly EBT Margin fell 21673.0% year-over-year to 1183.77% in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 1007.75% (down 10923.0% YoY) and the FY2025 annual result came in at 592.0%, up 90151.0% from the prior year.
- EBT Margin retreated to 1183.77% in Q2 2023 per MESO's latest filing, from 961.63% in the prior quarter.
- Over the last five years, EBT Margin for MESO reached as high as 134.96% in Q2 2020 and fell as low as 2607.97% in Q1 2019.
- A 5-year average of 1079.02% and a median of 1014.28% in 2022 frame the typical range for EBT Margin.
- The largest YoY upside for EBT Margin was 178057 bps in 2020 against a maximum downside of 154055 bps in 2020.
- Year by year, EBT Margin stood at 1363.79% in 2019, then advanced by 16 bps to 1143.15% in 2020, then soared by 36 bps to 736.0% in 2021, then sank by 56 bps to 1150.75% in 2022, then declined by 3 bps to 1183.77% in 2023.
- According to Business Quant data, EBT Margin over the past three periods registered 1183.77%, 961.63%, and 1150.75% for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -1,183.77% |
| Mar 31, 2023 | -961.63% |
| Dec 31, 2022 | -1,150.75% |
| Sep 30, 2022 | -763.36% |
| Jun 30, 2022 | -967.04% |
| Mar 31, 2022 | -1,061.51% |
| Dec 31, 2021 | -736.00% |
| Sep 30, 2021 | -937.53% |
| Jun 30, 2021 | -676.19% |
| Mar 31, 2021 | -1,359.19% |
| Dec 31, 2020 | -1,143.15% |
| Sep 30, 2020 | -1,936.70% |
| Jun 30, 2020 | -134.96% |
| Mar 31, 2020 | -827.39% |
| Dec 31, 2019 | -1,363.79% |
| Sep 30, 2019 | -396.15% |
| Jun 30, 2019 | -1,215.20% |
| Mar 31, 2019 | -2,607.97% |
| Dec 31, 2018 | -2,257.11% |
| Sep 30, 2018 | -1,845.57% |